Please login to the form below

Not currently logged in
Email:
Password:

patent cliff

This page shows the latest patent cliff news and features for those working in and with pharma, biotech and healthcare.

Lundbeck and Otsuka start phase III for Rexulti in bipolar

Lundbeck and Otsuka start phase III for Rexulti in bipolar

off the patent cliff in recent years and seen steep sales decline as a result, although a long-acting depot formulation (Abilify Maintena) is still making gains. ... Rexulti is one of a string of new drugs at Lundbeck - along with Abilify and

Latest news

  • Life lessons Life lessons

    In the case of generics, we’re seeing four variations emerge. Fast followers, like the biosimilar companies, compete by living very close to the edge of the patent cliff.

  • 2017 set to be a 2017 set to be a "defining year" for AZ

    With several new product launches due in 2017, AstraZeneca is hoping to draw a line under a tricky few years punctuated by the loss of patent protection for blockbuster brands. ... The last AZ drug to fall over the 'patent cliff' - cholesterol-lowerer

  • Surging sales of Lundbeck's CNS drugs assist recovery Surging sales of Lundbeck's CNS drugs assist recovery

    Surging sales of Lundbeck's CNS drugs assist recovery. Two newer antidepressants help boost sales after Cipralex patent ends. ... Surging sales of four new central nervous system drugs helped Denmark's Lundbeck post a 5% sales increase in the second

  • Pfizer maintains lead in top CNS drug sales - just Pfizer maintains lead in top CNS drug sales - just

    It is also now Pfizer's top-selling medicine after the 2012 patent expiry of its once £13bn a year statin Lipitor (atorvastatin). ... The drug will now start to lose a massive $6.2bn by 2019 as the result of generic competition, making it the biggest

  • Patent cliff losses set to cost pharma $65bn by 2019 Patent cliff losses set to cost pharma $65bn by 2019

    Patent cliff losses set to cost pharma $65bn by 2019. Lilly, AZ and Otsuka to be hit hard, says GlobalData. ... of the drug is not so positive with its US patent expiration in 2015, leading to a potential loss of $6.2bn by 2019.

More from news
Approximately 3 fully matching, plus 56 partially matching documents found.

Latest Intelligence

  • Change in the pharma industry is inevitable Change in the pharma industry is inevitable

    The industry’s patent cliff is nothing new but the targeted, specialist nature of the latest generation of drugs is making it increasingly challenging to deliver a return on investment within ... the 10-year window that a patent is in force.

  • Building a bright future Building a bright future

    the patent cliff of high-value biologics across Europe. ... We are in the front of a big patent cliff which creates a tremendous opportunity.”.

  • Pharma deals during August 2014 Pharma deals during August 2014

    Will the fools or angels win out? The prospect of lost revenues resulting from Lantus' tumble off the patent cliff next year seems to be sufficient motivation for Sanofi, one of

  • Back to the future Back to the future

    And at the same time, the impact of generic erosion and the patent cliff continues to wipe billions of dollars off their shareholder value. ... The leaders in pharma showed high levels of resilience through 2013, despite the continuing fallout from the

  • Pharma deals during February 2014 Pharma deals during February 2014

    given the loss of patent protection on Forest's best selling depression drug Lexapro and another patent cliff looming for Nameda, its Alzheimer's drug in 2015.

More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics